Captor Therapeutics Publishes Q1 2023 Financial Results
May 30, 2023 08:00 ET
|
Captor Therapeutics
Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to planSolid cash position...
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast
March 28, 2023 02:00 ET
|
Captor Therapeutics
CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancerStrong preclinical data generated with CT-02 against NEK7CT-05 potential best-in-class profile in high...
Captor Therapeutics Announces Three-Year Strategic Objectives
March 07, 2023 02:00 ET
|
Captor Therapeutics
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its...
Captor Therapeutics Reports Q3 2022 Results and Provides Business Update
November 25, 2022 08:00 ET
|
Captor Therapeutics
WROCŁAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for...
Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
November 14, 2022 07:00 ET
|
Captor Therapeutics
WROCŁAW, Poland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE: CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announces a worldwide...
Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma
August 10, 2022 01:00 ET
|
Captor Therapeutics
WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for...
Captor Therapeutics to Host R&D Day on May 18, 2022
May 05, 2022 03:00 ET
|
Captor Therapeutics
WROCŁAW, Poland, May 05, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer...
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma
April 12, 2022 01:00 ET
|
Captor Therapeutics
CT-01 compounds induce degradation of GSPT1, SALL4 and another as yet undisclosed neo-substrateThe unique degradation profile supports the strong competitive potential of the programCompelling...
Captor Therapeutics Invited to TPD Panel at the 8th Annual LSX World Congress 2022
April 11, 2022 02:00 ET
|
Captor Therapeutics
WROCLAW, Poland, April 11, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer...
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma
January 13, 2022 09:56 ET
|
Captor Therapeutics
Data confirm strong anticancer activity of two lead compounds in CT-01 programResults support advancement of CT-01 compounds towards IND expected in late 2022 WROCŁAW, Poland, Jan. 13, 2022 ...